Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Vera Therapeutics, Inc. VERA
$7.68
+$0.13 (1.72%)
На 18:04, 12 мая 2023
+156.12%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
340810470.00000000
-
week52high
23.39
-
week52low
5.20
-
Revenue
0
-
P/E TTM
-2
-
Beta
0.00000000
-
EPS
-3.72000000
-
Last Dividend
0.00000000
-
Next Earnings Date
28 мар 2023 г. в 11:30
Описание компании
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 22 авг 2022 г. |
| JP Morgan | Overweight | 12 июл 2022 г. | |
| HC Wainwright & Co. | Buy | 02 мая 2022 г. | |
| Wedbush | Outperform | 19 апр 2022 г. | |
| Jefferies | Buy | 08 июн 2021 г. | |
| JP Morgan | Overweight | Overweight | 18 ноя 2022 г. |
| Wedbush | Neutral | Outperform | 04 янв 2023 г. |
| Jefferies | Hold | Buy | 04 янв 2023 г. |
| HC Wainwright & Co. | Buy | Buy | 04 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Curley Joanne | D | 35801 | 2212 | 16 дек 2022 г. |
| Curley Joanne | D | 26821 | 783 | 16 дек 2022 г. |
| Curley Joanne | A | 27604 | 783 | 16 дек 2022 г. |
| Curley Joanne | A | 28250 | 1429 | 16 дек 2022 г. |
| Curley Joanne | D | 8639 | 1078 | 13 дек 2022 г. |
| Curley Joanne | D | 65384 | 11733 | 13 дек 2022 г. |
| Curley Joanne | A | 27899 | 1078 | 13 дек 2022 г. |
| Curley Joanne | D | 26821 | 1078 | 13 дек 2022 г. |
| Curley Joanne | A | 38554 | 11733 | 13 дек 2022 г. |
| Curley Joanne | D | 77117 | 6900 | 12 дек 2022 г. |
Новостная лента
Why Vera Therapeutics Stock Bolted Higher This Week
The Motley Fool
22 янв 2023 г. в 07:39
Vera's stock gained a noteworthy 49% this week.
Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)
Benzinga
10 янв 2023 г. в 07:33
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
VERA Dips Despite Positive Data From IgA Nephropathy Study
Zacks Investment Research
04 янв 2023 г. в 13:32
VERA posts positive top-line data from the phase IIb ORIGIN study evaluating atacicept for the treatment of IgA nephropathy.
Why Vera Stock Crashed 60% On Its 'Positive' Kidney Drug Update — And Chinook Popped
Investors Business Daily
04 янв 2023 г. в 10:05
A kidney disease treatment from Vera lagged rivals from Chinook and Otsuka, analysts said Wednesday as the biotech stock plummeted. The post Why Vera Stock Crashed 60% On Its 'Positive' Kidney Drug Update — And Chinook Popped appeared first on Investor's Business Daily.
Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 2022 Annual Meeting
GlobeNewsWire
17 окт 2022 г. в 07:30
BRISBANE, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, announced two new abstracts featuring new clinical data on the Company's two product candidates, MAU868 in kidney transplant and atacicept in immunoglobulin A nephropathy (IgAN). These data are to be presented in oral and poster sessions, respectively, at the American Society of Nephrology Kidney Week 2022 Annual Meeting, being held November 3-6, 2022 in Orlando, Florida. The oral presentation on MAU868 includes final results from the Phase 2 clinical trial of MAU868 versus placebo to treat BKV in kidney transplant patients. The poster presentation on atacicept includes a new analysis of previously presented clinical data from the Phase 2a JANUS clinical trial evaluating atacicept in patients with IgAN.